ALK and cancer: Genomic aberrations in oncogenes such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions have defined different molecular subtypes of NSCLC with unique cancer biology and response to matched tyrosine kinase inhibitors (TKI) [11].